Arimidex Observational: Reason for and Effect of Change From Tamoxifen

AstraZeneca200 enrolled

Overview

The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Postmenopausal * Hormone sensitive breast cancer * Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago Exclusion Criteria: * Visceral metastases * Patients with signs of progression at the moment of changing therapy * Patients who have used other endocrine treatments for breast cancer besides tamoxifen

Locations (33)

Research Site

's-Hertogenbosch, Netherlands

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.